Long-Acting Naltrexone Formulation for Alcohol Dependence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcohol dependence, particularly naltrexone therapies, face challenges with patient compliance and require strict alcohol abstinence and prior oral dosing, limiting their effectiveness.
Innovation Solution
A long-acting naltrexone formulation is administered parenterally, providing serum levels three times higher than oral administration, allowing for dosages between 160 mg to 480 mg every four weeks, without requiring prior oral naltrexone or alcohol abstinence, and can be used in conjunction with psychosocial treatment or alone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral naltrexone administration is used, then treatment can be provided, but patient compliance is poor and requires strict alcohol abstinence and prior oral dosing
Solution Approach 1:
The patent replaces the oral administration route with parenteral (injectable) delivery system. This substitution eliminates the need for daily patient self-administration, thereby improving compliance while maintaining treatment efficacy. The injectable formulation delivers naltrexone directly into the system, bypassing the compliance issues associated with oral medication.
Solution Approach 2:
The long-acting injectable formulation provides preliminary action by establishing sustained drug levels in the body before alcohol consumption occurs. This eliminates the need for prior oral dosing and strict abstinence requirements, as the medication is already present and active when needed.
2Reliability
If long acting formulation with high serum AUC is used, then treatment efficacy is improved, but dosage and administration complexity increases
Solution Approach 1:
The patent segments the total monthly naltrexone dose into smaller, manageable injectable units administered at specific intervals. The long-acting formulation is divided into microspheres or depots that release drug gradually over time, simplifying the administration schedule to once-monthly injections while maintaining high serum AUC levels.
Solution Approach 2:
The patent implements periodic action through monthly injectable administrations that provide sustained drug release over the treatment period. This periodic dosing strategy maintains therapeutic serum levels throughout the month, achieving high AUC values while keeping the administration schedule simple and regular.
Data Source
AI summary
The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.